Results 51 to 60 of about 153,102 (279)

Bcl-xL is the only anti-apoptotic Bcl-2 family member necessary for survival during KSHV latent infection.

open access: yes, 2023
(A) TIME cells were transduced with the indicated sgRNAs and selected as before and were subsequently mock or KSHV infected. Cell viability was measured with a trypan blue assay 48 hpi.
Michael Lagunoff (143637)   +4 more
core   +1 more source

Praf2 is a novel Bcl-xL/Bcl-2 interacting protein with the ability to modulate survival of cancer cells.

open access: yesPLoS ONE, 2010
Increased expression of Bcl-xL in cancer has been shown to confer resistance to a broad range of apoptotic stimuli and to modulate a number of other aspects of cellular physiology, including energy metabolism, cell cycle, autophagy, mitochondrial fission/
Maria Teresa Vento   +6 more
doaj   +1 more source

Bcl-xL is not required for survival during latent infection in other cell types.

open access: yes, 2023
(A) BCBL-1, cells were transduced with sgRNAs selected for using puromycin resistance for 4 days, then seeded at 1 x 105 cells/mL. Cell viability was measured using a trypan blue assay at 24, 48, 72, and 96 h post seeding. (B) BCBL-1 cells were seeded at
Michael Lagunoff (143637)   +4 more
core   +1 more source

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas [PDF]

open access: yesJournal of Hematology & Oncology, 2020
Abstract Background Patients with advanced T cell lymphomas (TCLs) have limited therapeutic options and poor outcomes in part because their TCLs evade apoptosis through upregulation of anti-apoptotic Bcl-2 proteins. Subsets of TCL cell lines, patient-derived xenografts (PDXs), and primary patient samples depend on Bcl-xL for survival.
Yonghan He   +15 more
openaire   +4 more sources

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells

open access: yesHaematologica, 2023
BCL-XL and BCL-2 are key anti-apoptotic proteins and validated cancer targets. 753B is a novel BCL-XL/BCL-2 proteolysis targeting chimera (PROTAC) that targets both BCL-XL and BCL-2 to the von Hippel-Lindau (VHL) E3 ligase, leading to BCLX L/BCL-2 ...
Yannan Jia   +19 more
doaj   +1 more source

The Effects of Thymoquinone on Viability, and Anti-apoptotic Factors (BCL-XL, BCL-2, MCL-1) in Prostate Cancer (PC3) Cells: An In Vitro and Computer-Simulated Environment Study [PDF]

open access: yesAdvanced Pharmaceutical Bulletin, 2019
Purpose: Since active plant ingredients can induce apoptosis in many tumors, in this study we evaluate the apoptotic effects of thymoquinone (TQ) on PC3 cells.
Javad Saffari_Chaleshtori   +3 more
doaj   +1 more source

Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. [PDF]

open access: yesPLoS ONE, 2013
Migration and invasion of malignant cells are prerequisites for cancer progression and metastasis. The Bcl-2 family of proteins consists of about 25 members and has been extensively studied in the context of apoptosis.
Bruno Christian Koehler   +9 more
doaj   +1 more source

Molecular Interactions of Prodiginines with the BH3 Domain of Anti-Apoptotic Bcl-2 Family Members.

open access: yes, 2013
Prodigiosin and obatoclax, members of the prodiginines family, are small molecules with anti-cancer properties that are currently under preclinical and clinical trials. The molecular target(s) of these agents, however, is an open question.
Ali Hosseini (383134)   +26 more
core   +1 more source

Bcl-XL: A multifunctional anti-apoptotic protein

open access: yesPharmacological Research, 2020
B-cell lymphoma-extra large (Bcl-XL) is one of the anti-apoptotic proteins of the Bcl-2 family that is localized in the mitochondria. Bcl-XL is one of the key regulators of apoptosis that can also regulate other important cellular functions. Bcl-XL is overexpressed in many cancers, and its inhibitors have shown good therapeutic effects.
Mingxue, Li   +4 more
openaire   +2 more sources

PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines

open access: yesFEBS Open Bio, EarlyView.
Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy